HuiChuangYiYiLiao

http://www.hytriage.com/

Weekly News Amount
Total
${lastRankDetail.pages.length}
Financing ${lastRankDetail.financing_pages.length}
Product ${lastRankDetail.product_pages.length}
Negative ${lastRankDetail.sentiment_pages.length}
Huichuanyi is a medical and health service company, focusing on building a POCT platform. Its main product is colloidal gold immunoassay analyzer, which is used for rapid diagnosis of tumor markers such as hepatitis A, hepatitis B, hepatitis C and AIDS, and heart diseases

Transactions

Funding 1 Fundings
Date Amount Round Relative News
Mar 2018 25 million CNY Undisclosed Investment News | HuiChuangYiYiLiao won a new round of financing of 25 million yuan from Yahui Fund

Signals

Events ${currentEventsPage.count} Events
Events (${currentEventsPage.count}) Date
Nothing Happens :-(
${e.desp} ${e.date}
News ${ rankDetail.pages.length } News Articles ${currentTimeRange.start} ~ ${currentTimeRange.end}
Article (${rankDetail.pages.length}) Tag
${article.en_title} ${article.tag}
Industry Financing Info

Research

Intelligence 0 Research Briefs

Competition

Competitors 3 Competitors
Company Industry Series Amount Announced Date

POLARIS BIOLOGY

POLARIS BIOLOGY is a company founded by teams from Cambridge University and Zhejiang University. It is committed to providing effective drug treatment programs for common malignant tumor patients and doctors, significantly improving the survival rate and quality of life of patients, transforming the latest research results of robot scientists into applied technologies for tumor treatment, and creating an internationally leading individualized guiding drug use method at cell level

Healthcare

series B

70 million CNY

24/6/2020

NuProbe

NuProbe's TOE HOLD PROBE - based technology is the initial research and development at Harvard University's Vis Institute of Bioengineering and Rice University, and is authorized by its patent. This is a breakthrough molecular technology that can be used to detect various diseases including cancer. NuProbe's technology can very sensitively identify mutants in the early stage, improve the detection rate of diseases and help guide treatment decisions that can increase patients' chances of survival

Healthcare

series A

11 million USD

23/4/2018

anobiomed

anobiomed is a cancer immunotherapy research and development company, focusing on technology research and development in tumor cell biology and immunology and other related fields. It has an antibody screening platform, a clinical lentivirus production platform and a cell gene editing platform, and research and development involves CART technology, which is applied to blood tumor patients to extend the remission period

Healthcare

series A

Tens of millions CNY

19/4/2018